AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M

ANAPTYSBIO, INC

ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.
Higher placebo rates than historical norms, particularly in U.S., contributed to failure; drug well tolerated with no safety signals.
Cash, equivalents and investments expected to be ~$415M at Dec 31, 2024, funding operations through year-end 2027.
One serious adverse event (worsening AD) across active arms; no dose relationship or imbalance in adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.